A Phase I/II Study of S-1 in Combination with Sorafenib in Patients with Metastatic Renal Cell Cancer

Trial Profile

A Phase I/II Study of S-1 in Combination with Sorafenib in Patients with Metastatic Renal Cell Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Taiho Pharmaceutical Company
  • Most Recent Events

    • 28 Apr 2014 New trial record
    • 01 Feb 2014 Phase II results presented at the 2014 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top